Expert Opinion on Drug Safety

Papers
(The H4-Index of Expert Opinion on Drug Safety is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Adverse event profiles of drug-induced decreased libido: an assessment of the US food and drug administration Adverse Event Reporting System132
An update on the cognitive safety of antimuscarinics in the treatment of overactive bladder125
Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting Sys99
Adverse events in patients with cardiovascular disease taking proton pump inhibitors51
Safety concerns associated with various types of statins: a disproportionality analysis of the FAERS database46
The safety of phthalate-containing medications used during pregnancy42
Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database39
Safety profile of isocitrate dehydrogenase inhibitors in cancer therapy: a pharmacovigilance study of the FDA Adverse Event Reporting System39
Novel insights into post-marketing AEs associated with bempedoic acid: a comprehensive analysis utilizing the FAERS database36
Why is pharmacovigilance essential for biosimilars?35
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile35
Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database33
Drug-induced hepatitis B virus reactivation: insights from FAERS database analysis32
The role of artificial intelligence in pharmacovigilance for rare diseases28
Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies28
Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects26
An updated safety review of Hidradenitis Suppurativa treatment options26
Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis26
A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting syst25
Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment25
Assessment of adverse events of the novel antiepileptic drug lamotrigine: a real-world pharmacovigilance study based on FAERS25
Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study24
A safety review of approved oral agents for treating type 2 diabetes and associated diseases in pregnant patients22
Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system22
Unveiling the hidden ocular risks of isotretinoin: a comprehensive FAERS-Based analysis22
Safety concerns associated with BACE1 inhibitors – past, present, and future22
2.1643550395966